Allison Jeynes is a pharmaceutical physician with over 30 years of senior leadership experience in the life sciences industry.
As CEO of Avillion since 2014, she has led the company to a 100% success rate in driving high-potential programs to regulatory approval across various therapy areas.
Allison earned her MD from the University of Sheffield and specialised in oncology at The Royal Marsden Hospital. She has held senior executive roles at Wyeth, Bristol-Myers Squibb, and Novartis, and has been responsible for around 20 drug approvals in the EU and US.
In addition to her role at Avillion, she serves on the Board of Directors for Anaveon and Uniquity Bio, and as Chair of Siolta Therapeutics. Allison is committed to advancing innovative therapies and improving patient outcomes.
Mary Sheahan is the Chief Financial Officer at Avillion, bringing over 20 years of experience in biotech and pharmaceutical sectors. She has been involved in the development and launch of products, particularly in neurology, immunology and respiratory.
Previously, she held senior executive roles at Perrigo Company and Elan Corporation. She has served as a member of the Supervisory Board and Audit Committee Chair at the Biodata company Centogene and the CRO Venn Life Sciences.
Mary is a qualified Chartered Accountant with a background in finance, portfolio management, and HR. She began her career with KPMG after completing her studies at University College Dublin.
Anna Danilewicz has over 25 years of experience in global clinical development, leading complex projects and large teams. She has been pivotal in securing 12 marketing authorisations and driving Avillion’s mission to bring new therapies to market efficiently. Anna has managed clinical trial operations in over 30 countries across various therapeutic areas, including oncology, respiratory, endocrinology, autoimmune, rare diseases, cardiology, and neurology.
She holds a Bachelor of Science honours degree in Biology from the University of Southampton.
Jason has over 25 years of experience in global drug, biological, and combination-product development, focusing on complex products, rare diseases, and integrating science, medicine, law, regulation, and business. He has worked in various therapeutic areas, including oncology, respiratory, endocrinology, autoimmune and infectious diseases, ophthalmology, neurodegenerative disorders, and gastroenterology.
He has played a key role in ensuring Avillion’s clinical programs meet regulatory standards, advancing the company’s mission to accelerate the availability of new drugs.
He holds an MS and MBA, along with US and Global RAC designations. Jason is US based.
Robert Rees brings extensive experience in global study management. At Avillion, he was the operational lead for the AIRSUPRA registrational program, resulting in FDA approval for asthma treatment in January 2023. He also managed the pivotal phase 3 trial (BFORE) leading to sNDA approval for Bosulif in Chronic Myeloid Leukaemia (CML).
With prior roles at Amgen and Eli Lilly, Rob has a proven record in oncology, respiratory, endocrinology, and haematology.
He holds a PhD in Biological Sciences from the University of Bath and a BSc (1st class) from the University of Edinburgh.
Dr Frank Albers has over 20 years of experience in the pharmaceutical industry, focusing on Global Clinical Development and Medical Affairs. He specialises in Phase II-IV drug development, life cycle management, and real-world studies, particularly in respiratory, allergy, immunology, and immuno-inflammation.
Frank has been instrumental in preparing and submitting three NDA/BLA reviews. As the Senior Global Medical Lead for the PT07 program, he oversees protocols, clinical study reports, medical monitoring, pharmacovigilance, and safety reporting activities.
Frank has co-authored over 30 peer-reviewed publications. Frank is US based.